This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.08% per year. These returns cover a period from January 1, 1988 through May 6, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Thousand Oaks, CA-based Amgen is one of the biggest biotech companies in the world, with a strong presence in the oncology/hematology, cardiovascular disease, neuroscience, inflammation, bone health and nephrology markets. The company used advances in cellular and molecular biology to develop two of the biotech industry’s earliest and most successful drugs, Epogen (anemia) and Neupogen (white blood cell stimulant). Amgen successfully launched two next-generation products, Aranesp and Neulasta. Meanwhile, the acquisition of Immunex Corporation gave Amgen access to the multi-blockbuster drug, Enbrel. However, all these older drugs are facing declining sales due to biosimilar or branded competition, which is being somewhat offset by its newer blockbuster drugs like Prolia/Xgeva
Does Amgen Offer a Great Value Buying Opportunity Right Now?
by Zacks Equity Research
Is Amgen a great pick from the value Investor's perspective right now? Read on to know more.
Biotech Stock Roundup: Amgen's Data on Repatha, Catalyst Soars on Firdapse Data
by Arpita Dutt
The biotech sector reacted favorably to President Donald Trump's pick for the top post in the FDA.
Merck's (MRK) Keytruda Gets FDA Nod for Lymphoma Indication
by Zacks Equity Research
Merck & Co., Inc (MRK) announced that it has received FDA approval for Keytruda for the treatment of patients with refractory classical Hodgkin lymphoma (cHL) or who had relapsed after three or more prior lines of therapy.
Amgen's Repatha Meets Primary Endpoint in Phase III Study
by Zacks Equity Research
Amgen, Inc. (AMGN) announced positive data from a phase III study evaluating Repatha in patients who were receiving apheresis to help control their low-density lipoprotein cholesterol (LDL-C).
Why Amgen (AMGN) Stock Rallied After Q4 Earnings Release?
by Zacks Equity Research
Biotech major, Amgen, Inc.'s (AMGN) shares have risen 12.1% since it reported better-than-expected fourth quarter results on Feb 2.
J2 Global, eHealth, Pfizer, Amgen and Mylan highlighted as Zacks Bull and Bear of the Day
by Zacks Equity Research
J2 Global, eHealth, Pfizer, Amgen and Mylan highlighted as Zacks Bull and Bear of the Day
Novartis (NVS) Reports Positive Data on Biosimilar Humira
by Zacks Equity Research
Novartis AG (NVS) announced encouraging data for its proposed biosimilar verison of AbbVie's (ABBV) Humira.
Mylan (MYL) Beats on Q4 Earnings, Stock Up on Strong View
by Zacks Equity Research
Shares of Mylan N.V.'s (MYL) were up 7.2% after the company beat expectations in the fourth-quarter 2016 and provided a strong outlook for 2017 amid challenging conditions.
Pricing to Remain Pharma Headline Risk in 2017
by Arpita Dutt
Drug pricing is an issue that has been weighing on pharma and biotech stocks for more than a year now.
by Zacks Equity Research
Pharma Industry Outlook - February/March 2017
by Arpita Dutt
The sector is showing signs of recovery with the NYSE ARCA Pharmaceutical Index gaining 5.1% while the NASDAQ Biotechnology Index is up 7.3%.
Ligand (LGND) Q4 Earnings Down Y/Y, Revenues Miss Estimates
by Zacks Equity Research
Ligand Pharmaceuticals Incorporated (LGND) reported fourth-quarter 2016 earnings of 50 cents per share (including the impact of stock-based compensation expense), down 11.1% from the year-ago figure.
The Zacks Analyst Blog Highlights: Amgen, Procter & Gamble, Bank of America, Netflix and Honda
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Amgen, Procter & Gamble, Bank of America, Netflix and Honda
Mylan's Proposed Biosimailar for Cancer Under Review in U.S.
by Zacks Equity Research
Mylan N.V. (MYL) and Biocon Ltd. announced that the FDA has accepted their biologics license application for a biosimilar version of Amgen's (AMGN) Neulasta (pegfilgrastim) - MYL-1401H.
Valeant's (VRX) Plaque Psoriasis Drug Approved in the U.S.
by Zacks Equity Research
Valeant Pharmaceuticals (VRX) recently announced that the the FDA has approved its Biologic License Application (BLA) for Siliq (brodalumab) injection the treatment of moderate-to-severe plaque psoriasis in adult patients.
Pfizer's Xeljanz Combo Comparable to AbbVie's Humira
by Zacks Equity Research
Pfizer, Inc. (PFE) announced top-line results from a head-to-head study comparing its rheumatoid arthritis (RA) drug Xeljanz with AbbVie, Inc.'s (ABBV) Humira.
Amgen Looking to Broaden Leukemia Drug Blincyto's Label
by Zacks Equity Research
Biotech major Amgen Inc. (AMGN) announced that it has submitted a supplemental biologics license application (sBLA) to the FDA for its leukemia immunotherapy Blincyto.
Regeneron (REGN) Misses on Q4 Earnings & Sales, View Bleak
by Zacks Equity Research
Regeneron Pharmaceuticals, Inc. (REGN) reported disappointing results for the fourth quarter of 2016. The outlook for 2017 did not give investors anything to cheer for either.
Sanofi (SNY) Q4 Earnings In Line; Can Sell Praulent for Now
by Zacks Equity Research
Sanofi (SNY) reported fourth-quarter 2016 earnings of 67 cents per American depositary share, which was in line with the Zacks Consensus Estimate.
Regeneron (REGN) Q4 Earnings: Will the Stock Disappoint?
by Zacks Equity Research
Regeneron Pharmaceuticals, Inc. (REGN) is scheduled to release fourth-quarter 2016 results on Feb 9, before the opening bell.
Allergan (AGN) Tops Q4 Earnings; 2017 Sales View Upbeat
by Kinjel Shah
Allergan plc's (AGN) fourth-quarter 2016 earnings came in at $3.90 per share, beating the Zacks Consensus Estimate of $3.79 by 2.9%.
Amgen's Secondary Hyperparathyroidism Drug Approved in U.S.
by Zacks Equity Research
Amgen Inc. (AMGN) announced that the FDA has approved Parsabiv (etelcalcetide) for the treatment of secondary hyperparathyroidism (HPT) in adult patients with chronic kidney disease (CKD) on hemodialysis.
Biotech Stock Roundup: Amgen, Gilead Report 4Q Results, ARIAD Seeks EU Nod for Brigatinib
by Arpita Dutt
Although both Amgen (AMGN) and Gilead reported better-than-expected 4Q results, the companies provided a disappointing sales outlook for 2017.
Merck???s Keytruda Gets Priority Review for Bladder Cancer
by Zacks Equity Research
Merck & Co., Inc.???s (MRK) two supplemental Biologics License Applications (sBLA) for its anti-PD-1 therapy, Keytruda, have been accepted under priority review by the FDA.
Are Options Traders Betting on a Big Move in Amgen (AMGN) Stock?
by Zacks Equity Research
Investors in Amgen Inc. (AMGN) need to pay close attention to the stock based on moves in the options market lately.